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Abstract 1 
Pre-eclampsia affects between 2-7% of pregnant women. There are conflicting data on plasma 2 
homocysteine and folate in pre-eclampsia, and little about fetal concentrations.  3 
Objectives: To compare the concentrations of homocysteine and folate in maternal and paired fetal 4 
(umbilical venous) plasma samples from normotensive or pre-eclamptic pregnancies at delivery and to 5 
identify any effect of parity on these concentrations.  6 
Study design: Hospital based cross-sectional study of 24 normotensive and 16 pre-eclamptic pregnant 7 
women from whom maternal and fetal plasma samples were collected at delivery.  8 
Main outcome measures: Maternal and fetal plasma homocysteine and folate concentrations between 9 
normotensive and pre-eclamptic pregnancies with varying parity. 10 
Results: There were no significant differences in either maternal or fetal plasma homocysteine or folate 11 
concentrations between normotensive and pre-eclamptic pregnancies. In both the normotensive and 12 
pre-eclamptic women, plasma folate concentration was higher in paired fetal compared to maternal 13 
plasma (P < 0.001 and P = 0.047 respectively).  Both maternal and fetal plasma folate concentrations 14 
were lower in parous women (P = 0.001; P = 0.017 respectively), the lowest concentrations being in 15 
pre-eclamptic parous women (P = 0.004), but homocysteine concentrations were similar.  16 
Conclusions: The low plasma folate in parous women is an interesting finding and, when intake is also 17 
low, may contribute to adverse pregnancy outcomes, particularly in relation to pre-eclampsia.  18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 3 
Introduction 26 
Pre-eclampsia is estimated to occur in 2-7% of all pregnancies and is a leading cause of maternal and 27 
perinatal mortality and morbidity in the Western world [1]; together with other hypertensive disorders 28 
of pregnancy it is responsible for approximately 60,000 deaths each year [2]. Pre-eclampsia is now 29 
commonly regarded as being a state of oxidative stress [3]. It is thought that primarily inadequate 30 
placental perfusion results in excessive production of reactive oxygen species giving rise to endothelial 31 
cell dysfunction and thus clinical manifestations of pre-eclampsia [4].   32 
Homocysteine is a metabolic product of methyl-group donation by the amino acid methionine; 33 
remethylation is catalysed by folate.  Small increases in plasma homocysteine concentrations are 34 
associated with increased risk of vascular disease [5], Alzheimer’s disease [6] and neural tube defects 35 
[7] in the general population. Elevated homocysteine concentrations contribute to oxidative stress and 36 
endothelial dysfunction [8] and are thus also potentially implicated in the pathogenesis of pre-37 
eclampsia. Some studies report raised homocysteine concentrations in pre-eclampsia (e.g. [9, 10]) 38 
while others have shown no significant differences [11, 12]. Maternal and fetal plasma homocysteine 39 
concentrations have been reported to be directly correlated in healthy nulliparae [13] and do not appear 40 
to change significantly during the course of pregnancy [14]. If plasma homocysteine concentrations are 41 
indeed raised in pre-eclampsia, and there is similar parallelism, then the fetus will be exposed to 42 
potentially damaging levels of homocysteine even before birth, which might have long-term 43 
consequences. Important factors influencing homocysteine concentrations are folate and vitamin B12 44 
status and the methylenetetrahydrofolate reductase (MTHFR) polymorphisms [15]; once again the data 45 
on these in pre-eclampsia is conflicting [16, 17].     46 
There is considerably less, but similarly conflicting, evidence linking folate concentrations and pre-47 
eclampsia [18, 19]. The fetus must receive an adequate supply of folate for growth and development; 48 
inadequate concentrations will also, inter alia, impede the remethylation of homocysteine. Both 49 
metabolites have active transport systems in the placenta [20] and impaired placentation is believed to 50 
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be central to the pathogenesis of pre-eclampsia. Folate has recently been shown to possibly play a 51 
direct role in extravillous trophoblast invasion [21], thus highlighting the need for adequate folate 52 
concentrations pre-pregnancy and during the early stages of pregnancy. Studies linking homocysteine 53 
and folate in the mother and fetus are very limited [17]. We therefore felt it to be important to measure 54 
fetal, as well as maternal, concentrations of homocysteine and folate at delivery. 55 
Folate intake among women of reproductive age in the UK is reported to be low [22]. There is an 56 
increased demand for folate during pregnancy, which can result in suboptimal folate status [23], 57 
although there is some evidence to suggest that folate turnover during pregnancy does not appear to 58 
change if folate intake is adequate [24]. Increasing parity has been associated with decreasing plasma 59 
folate concentrations [25, 26],  presumably because lactation is a further drain on folate reserves [27]. If 60 
dietary intake is suboptimal, these stores may not be replenished before a subsequent pregnancy, 61 
especially in cases of short inter-pregnancy intervals [25, 28]. We are unaware of any studies relating 62 
these low folate levels to increased plasma homocysteine concentrations in either parous women as a 63 
group, or parous women who develop pre-eclampsia. However, there is indirect evidence for an 64 
interaction between parity and raised plasma homocysteine concentrations which has been related to 65 
increased risk of pre-eclampsia [29, 30]. We hypothesised that plasma folate concentrations would be 66 
lower, and homocysteine higher, in pre-eclamptic women and their babies than in normotensive 67 
pregnant controls. We also opportunistically examined the effect of parity on maternal plasma folate 68 
concentrations in normal and pre-eclamptic pregnancy.   69 
 70 
 71 
 72 
 73 
 74 
 75 
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Methods 76 
Subjects:  These investigations formed part of a detailed study of selenium and glutathione peroxidases 77 
in pregnancy, requiring recruitment of 25 pregnant women to each arm (see: [31]). The current study 78 
had a power of 80% to detect a difference of 1SD in maternal plasma folate concentration between the 79 
24 normotensive and 16 pre-eclamptic women at the 5% level from whom paired maternal and fetal 80 
samples were available. Approval for these investigations was given by the Nottingham Hospital Ethics 81 
Committee and written informed consent was obtained from each participant.  The study population 82 
consisted of two groups of White European women: normotensive and pre-eclamptics (Table 1). Paired 83 
fetal samples were also obtained via umbilical venous plasma. Cases were defined on admission with a 84 
clinical diagnosis of pre-eclampsia, using the International Society for the Study of Hypertension in 85 
Pregnancy definition of blood pressure ≥ 140/90 mm Hg (Korokoff V) on 2 occasions after 20 weeks 86 
gestation and proteinuria > 300 mg/L, 500 mg/day or 2+ on dipstick [32]. Controls were healthy with 87 
no pregnancy or medical complications. 88 
Sample collection: Non-fasting venous blood samples were taken from mothers before delivery; where 89 
possible, umbilical venous samples were also taken immediately after placental delivery, in EDTA.  90 
Samples were transported on ice to the laboratory and centrifuged at 1,400 x g for 10 minutes at 4oC 91 
and plasma was immediately stored at -80oC until analysis. 92 
Homocysteine measurements: Measurements of plasma homocysteine concentrations were obtained via 93 
fluorescence polarization immunoassay on the Abbott AxSym analyser.  This assay has an analytical 94 
range of 1-50 µmol/L and reproducibility (CV) of 5.5% at 7.4 μmol/L, 6.2% at 13.5 μmol/L, and 5.4% 95 
at 25.9 μmol/L. 96 
Folate assay:  A microbiological technique with a chloramphenicol-resistant strain of Lactobacillus 97 
rhamnosus (L. rhamnosus) was used to assess the plasma folate concentrations as described previously 98 
[33]; 15 mg/ml manganese sulphate was added to the buffer to avoid artificially low plasma folate 99 
values [33, 34].  The inter- and intra-assay CVs were 5% and 4% respectively.  100 
 6 
Statistical analysis: All tests were performed using SPSS for Windows version 14.0.  Summary data 101 
are presented as medians [interquartile range (IQR)] or means ± SD depending on the distribution. The 102 
Kolmogorov-Smirnov test was used to assess the distribution of the data. Between group comparisons 103 
were made using Kruskal-Wallis tests or 2-tailed Student’s t tests/Mann-Whitney U-tests depending on 104 
the distribution. Wilcoxon Signed Ranks tests were used to carry out paired comparison. Multiple 105 
regression analysis for maternal folate and parity correcting for inter-pregnancy interval and number of 106 
previous pregnancies were conducted. Correlations between the parameters were tested using 107 
Spearman’s Ranks correlation test. The null hypothesis was rejected where P < 0.05.   108 
 109 
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 120 
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Results 126 
Subjects: Both groups conceived spontaneously, carried singleton pregnancies and all neonates 127 
survived.  Normotensive pregnant women delivered without developing hypertension or proteinuria, 128 
having infants weighing > 2500 g, delivered at 37 weeks’ gestation or later.  The systolic and diastolic 129 
blood pressure levels were, by definition, significantly raised in pre-eclampsia compared to normal 130 
pregnancy (P < 0.0001 for both; Table 1).  Overall, the pre-eclamptic women all had moderate-to-131 
severe disease (see[31]). 132 
Biochemical and molecular measurements: Maternal and fetal plasma homocysteine and folate 133 
concentrations are given in Table 1. Plasma homocysteine concentrations were very similar in 134 
normotensive and pre-eclamptic women; fetal concentrations were also very similar in the two groups. 135 
Maternal and fetal homocysteine concentrations were significantly positively correlated (r = 0.68, R2 = 136 
0.68, P < 0.0001). Fetal homocysteine concentrations were higher than maternal in normotensive (P = 137 
0.002), but not pre-eclamptic (P > 0.1) pregnancy. 138 
Maternal folate appeared higher in normal than pre-eclamptic pregnancy, but there this was not 139 
statistically significant due to the large range of data. Fetal plasma folate concentration did not differ 140 
across groups (Table 1) and were positively correlated with maternal concentrations (r = 0.44, R2 = 141 
0.20, P = 0.005). Fetal folate concentrations were higher than maternal in normotensive (P < 0.001) and 142 
pre-eclamptic (P = 0.047) pregnancies. Correlation analysis showed no evidence for an association 143 
between plasma homocysteine and folate concentrations in either maternal or umbilical venous plasma 144 
(r = 0.07, R2 = 0.03, P > 0.6; r = 0.09, R2 = 0.023, P > 0.4 respectively). 145 
Folate concentrations and parity: Overall, parous women and their babies had significantly lower 146 
plasma folate concentrations (Maternal: 6.0 [4.9, 6.8]; Fetal 18.2 [10.8, 22.2]) than nulliparous women 147 
(13.5 [7.5, 19.3]; P = 0.001) and babies (23.8 [17.2, 33.4]; P = 0.017; Figure 1a and b). Moreover, in 148 
both normotensive and pre-eclamptic women, parous women had significantly lower folate 149 
concentrations (normotensive: 6.2 [4.8, 10.4] cf pre-eclamptic: 5.4 [5.0, 6.2]; P = 0.006) compared to 150 
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nulliparous women (normotensive: 14.3 [10.2, 20.8] cf pre-eclamptic: 11.4 [6.2, 17.6]; P = 0.015; 151 
Figure 1b). Parous pre-eclamptic women had the lowest plasma folate concentrations (ANOVA; P = 152 
0.004). This difference was maintained when considered with respect to fetal plasma folate but only in 153 
the normotensive group (parous: 13.8 [10.4, 21.8] cf nulliparous 17.3 [11.5, 25.5]; P = 0.015).  A 154 
Kruskal-Wallis test showed that maternal folate concentrations were significantly different (P = 0.006) 155 
between nulliparous women and women who had had one or two previous pregnancies. Subsequent 156 
Mann-Whitney U tests indicated that the maternal folate concentrations were significantly higher in 157 
nulliparous women compared to parous women with 1 (P = 0.005) and 2 previous (P = 0.037) 158 
pregnancies (Table 2). Multiple regression analysis correcting for confounding factors thought to 159 
influence maternal plasma folate concentrations (inter-pregnancy intervals, number of previous 160 
pregnancies) indicated parity as an independent factor.  No similar effect was seen with respect to 161 
homocysteine. 162 
 163 
164 
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Discussion 165 
Although small, this cross-sectional study reports both maternal and fetal homocysteine and folate 166 
concentrations in normotensive and pre-eclamptic pregnancies; there appears to be little comparable 167 
maternal:fetal data from European populations [17]. Our maternal data are consistent with the results of 168 
other European studies in which no association was found with respect to homocysteine or folate 169 
concentrations and normotensive and pre-eclamptic pregnancies [11, 12].  Homocysteine has been 170 
potentially linked to processes such as inflammation [35] and hypercoagulation [8], which are present 171 
in severe pre-eclampsia. However, this does not mean that hyperhomocysteinaemia is a requirement for 172 
the development of pre-eclampsia and the elevated homocysteine concentrations seen in some pre-173 
eclamptic patients may be an associated, or pre-disposing, rather than a causal factor.  174 
Folate plays an essential role in the growth of the placenta from early pregnancy; folate deficiency has 175 
been linked to placental abruption and thus restricted fetal growth [36]. We observed no significant 176 
differences between maternal or fetal samples from normotensive pregnancy or pre-eclampsia. Most 177 
folate concentrations were within the reference range (7 – 46 nmol/L [37]) for non-pregnant UK adults, 178 
using this methodology, but 9 normotensive pregnant (7 parous) and 12 pre-eclamptic (6 parous) 179 
women had concentrations below this level and the pre-eclamptic patients had the lowest median 180 
values, which is consistent with previous studies examining folate concentrations [10, 17, 38]. Having 181 
folate concentrations at the lowest end of the range may contribute to the pathological consequences of 182 
oxidative stress as folate has been reported to have antioxidant properties [39].   The placenta takes up 183 
folate from the maternal circulation against a concentration gradient through a high-affinity binding 184 
site, the folate receptor-[40], and releases it into the fetal circulation through the reduced folate 185 
carrier. Further functional studies are required to ascertain the changes folate transport in adequate and 186 
deficient folate concentrations. 187 
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Women in the UK have moderately low folate intakes for the developed world [41]; in our laboratory, a 188 
group of normotensive, non-pregnant women of comparable age had a median folate concentration of 189 
13.9 nmol/L, relatively low in the reference range [37].  Periconceptual dietary supplementation with 190 
folic acid is widely advocated for the prevention of neural tube defects. However, only four women in 191 
normotensive and two women in the pre-eclamptic group (Table 1) took folic acid supplementation in 192 
this study. Unless there is dietary supplementation with folic acid, maternal folate concentrations in 193 
both plasma and red blood cells fall from about the fifth month of pregnancy [42]. 194 
Although sample sizes were small, we observed lower plasma folate concentrations in parous mothers 195 
and their babies in our study (Fig 1a), a trend exacerbated when pre-eclampsia supervened (Fig 1b). We 196 
do not know whether the parous women began pregnancy with lower stores or whether the uptake or 197 
renal reabsorption of folate differs in parous women. Larger studies are required to investigate this 198 
further especially by the findings from our group to indicate that folate may be essential early in 199 
pregnancy possibly directly promoting extravillous trophoblast invasion [21]. As only two women had 200 
3 previous pregnancies, statistical tests could not be performed. These women did however have 201 
maternal plasma concentrations of 6.2 and 6.6 nmol/L respectively, which are all approximately half of 202 
the nulliparous folate concentrations (Table 2). This suggests that regardless of how many previous 203 
pregnancies a woman has had, her folate concentrations appear to be significantly lower than 204 
nulliparous women. Qvist et al also showed that by 2 -3 months after delivery, a third of all mothers 205 
can have subnormal concentrations of folate in serum and red blood cells, both those who are and those 206 
who are not breast-feeding [42]. Furthermore, it has been reported that by 6 months postpartum, 20% of 207 
mothers were still folate deficient [43]. The low plasma folate concentration in parous women 208 
independent of inter-pregnancy interval suggest possible beneficial effects of pre-pregnancy folic acid 209 
supplementation particularly in parous women who have previously suffered from pre-eclampsia. 210 
Despite public health campaigns recommending the use of pre-conceptual folic acid supplementation, 211 
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the dietary intake of folic acid is still inadequate in about 13 million people within the UK [44]. Further 212 
investigations using larger cohorts are underway to further examine these fascinating initial data. 213 
 214 
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Table 1. Maternal and fetal venous plasma homocysteine and folate and participant details  351 
 352 
Parameter Normotensive pregnant 
n = 24 
Pre-eclampsia 
n = 16 
Maternal age (years)† 29 ± 6.6 31 ± 5.8 
Booking body mass index (kg/m2) † 25.9 ± 5.6 25.7 ± 3.8 
Primipara n (%) 15 (62.5) 11 (68.8) 
Max. systolic blood pressure (mm Hg)† 116 ± 4.3 157 ± 7.4# 
Max. diastolic blood pressure (mm Hg)† 76 ± 2.5 98 ± 4.9# 
Proteinuria (g/L) ‡ - 1.0 [0.5, 1.8] 
Gestation age at delivery, wks 39.8 ± 1.0 38.1 ± 2.0# 
Folate supplementation n (%) 4 (16.7) 2 (12.5) 
Maternal homocysteine (µmol/L)‡ 8.7 [ 6.8, 11.0] 8.2 [7.0, 10.6] 
Fetal homocysteine (µmol/L) ‡ 10.5 [9.0, 12.4]* 9.5 [7.4, 11.9] 
Maternal folate (nmol/L) ‡ 10.7 [6.2, 19.4] 6.8 [5.3, 14.1] 
Fetal folate (nmol/L) ‡ 22.2 [17.8, 32.7]* 16.4 [11.3, 23.4]* 
 353 
# P < 0.05 between normotensive and pre-eclamptic pregnancies; *P < 0.05 between maternal and fetal 354 
samples. †Values represented as means ± SD; ‡values represented as median [IQR]. Further 355 
demographic and pregnancy outcome details have been previously published[31]. 356 
 357 
 358 
 359 
 360 
 361 
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Table 2. Maternal plasma folate concentrations in women with different parities. 362 
Parity Maternal Folate, nmol/L 
(median [IQR]) 
0 (n = 24) 13.5 [6.9, 19.4] 
1 (n = 11) 5.6 [ 4.5, 8.0]** 
2 (n = 5) 6.0 [6.0, 6.8]* 
 363 
*P = 0.037 between nulliparous and two previous pregnancies; **P = 0.005 between nulliparous and 364 
one previous pregnancy. 365 
366 
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Figure Legends 367 
Figure 1. a) Maternal and fetal plasma folate concentrations by parity (nulliparous: white or parous: 368 
grey) in all pregnancies. 369 
b) Maternal plasma folate concentrations by both parity (nulliparous: white or parous: grey) and the 370 
presence or absence of pre-eclampsia. There was a significant effect across parity:group for both 371 
maternal (P = 0.006) and fetal (P = 0.015) samples. Maternal and plasma folate concentrations were 372 
lowest in pre-eclamptic, parous women.  373 
374 
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